With the world waiting, Roche socks $459M into COVID-19 antibody test production

Roche received the FDA's emergency use nod for its COVID-19 antibody test late last week. (Roche)

Roche scored a major win with the FDA's backing for its COVID-19 antibody tests last week in a field marked by products of questionable quality. Now, to cover its booming production goals, Roche plans to infuse nearly half-a-billion dollars into its German manufacturing facility. 

Roche will plow $459 million into its manufacturing facility in Penzberg, Germany, to boost production of the antibody test that won an emergency use authorization from the FDA last week, Reuters reported

At a German Ethics Council meeting Monday, officials said the government had signed a deal with Roche to secure 3 million diagnostic tests in May and an additional 5 million each following month. Eventually, Roche will aim to produce nearly 100 million tests per month by the end of 2020, according to Reuters. 

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

Roche is reportedly also working on a four-year plan to develop a brand-new research and diagnostic center. 

After the FDA approval Friday, Roche said it is prepared to produce "high double-digit millions" of the tests in May with the intent to continue ramping up production. 

RELATED: COVID-19 antibody testing 'a disaster,' says Roche CEO, as diagnostics sales rise

Roche began testing its antibody diagnostic, which runs on its high-throughput Elecsys assay platform and cobas line of analyzers, in mid-April.

During a first-quarter earnings call with analysts late last month, Roche CEO Severin Schwan blasted the current state of COVID-19 serology tests, calling many of the diagnostics "amateur."

“These tests are not worth anything, or have very little use,” Schwan said at the time. “Some of these companies, I tell you, this is ethically very questionable to get out with this stuff." 

RELATED: FDA grants Roche coronavirus test emergency green light within 24 hours

Roche has not only scored an emergency use nod for antibody tests but also for a fully automated molecular test for active COVID-19 patients. 

The FDA authorized Roche's diagnostic test in mid-March, just 24 hours after receiving the application. Previously, the FDA had only allowed specific, certified laboratories to use their preapproved and validated diagnostics in identifying COVID-19 patients.

Now, this latest Emergency Use Authorization enables clinicians to run the Roche test on the company’s cobas 6800/8800 molecular testing systems, widely available at hospitals and labs throughout the country. It is also available in European countries accepting the CE mark.

Suggested Articles

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.

The only thing certain about 2020 has been uncertainty, leaving almost everyone wondering what might come next.

Since the FDA released new COVID-19 vaccine guidance, HHS Secretary Alex Azar has discussed firing FDA Commissioner Stephen Hahn, Politico reports.